Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Marius van der Mooren

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Physiology

Postmenopause

Procedures

Chemicals & Drugs

Concepts & Ideas

Disorders

Cardiovascular Diseases

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
58
Kenemans, Peter
25
Mijatovic, Velja
20
van Baal, Marchien
17
Stehouwer, Coen
12
Vogelvang, Tatjana
11
Smolders, Raimond
10
Teerlink, Tom
9
Hemelaar, Majoie
8
Netelenbos, Coen
8
Post, Marinka
8
Verhoeven, Marieke
7
Schalkwijk, Casper
6
Emeis, Jef
5
Jakobs, Cornelis
5
Kessel, H

Sign-in to see all Coauthors

Publications

TOP 3
de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
Verhoeven Marieke O; van der Mooren Marius J; Teerlink Tom; Verheijen René H M; Scheffer Peter G; Kenemans Peter
The influence of physiological and surgical menopause on coronary heart disease risk markers.
Hemelaar Majoie; van der Mooren Marius J; Rad Mandana; Kluft Cornelis; Kenemans Peter
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Marius van der Mooren (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial.
European journal of obstetrics, gynecology, and reproductive biology 2009;142(2):139-44.
2009: Verhoeven Marieke O; van der Mooren Marius J; Teerlink Tom; Verheijen René H M; Scheffer Peter G; Kenemans Peter
The influence of physiological and surgical menopause on coronary heart disease risk markers.
Menopause (New York, N.Y.) 2009;16(1):37-49.
2008: Hemelaar Majoie; van der Mooren Marius J; Rad Mandana; Kluft Cornelis; Kenemans Peter
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review.
Fertility and sterility 2008;90(3):642-72.
2008: Korstjens Iolente J M; van der Mooren Marius J; Kloosterboer Helenius J; Sipkema Pieter
3beta-OH-tibolone acutely dilates rat muscle arterioles similar to 3alpha-OH-tibolone.
Menopause (New York, N.Y.) 2008;15(2):386-7.
2008: Hemelaar Majoie; Kenemans Peter; Hack C Erik; Klipping Christine; van der Mooren Marius J
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
Menopause (New York, N.Y.) 2008;15(2):248-55.
2007: Verhoeven Marieke O; Hemelaar Majoie; Teerlink Tom; Kenemans Peter; van der Mooren Marius J
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study.
Atherosclerosis 2007;195(1):181-8.
2007: Franke Henk R; Brood-van Zanten Monique M A; Burger Curt W; van der Mooren Marius J; Kenemans Peter
Breast cancer and climacteric complaints: weighing up risks of hormone therapy against quality of life.
European journal of obstetrics, gynecology, and reproductive biology 2007;134(2):143-6.
2007: Verhoeven Marieke O; Teerlink Tom; Kenemans Peter; Zuijdgeest-van Leeuwen Sonja D; van der Mooren Marius J
Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women.
Fertility and sterility 2007;87(4):849-57.
2007: Verhoeven Marieke O; Teerlink Tom; Kenemans Peter; Vogelvang Tatjana E; van der Mooren Marius J;
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
Menopause (New York, N.Y.) 2007;14(2):235-42.
2006: Franke Henk R; Snaaijer F Froukje; Houben Paul W H; van der Mooren Marius J
Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2006;22(12):692-7.
2006: Franke Henk R; Jordaan Anne-Fleur; Wolbers Floor; Vermes Istvan; Oostrom Karine A M; van der Mooren Marius J
Ex vivo measurement of cell apoptosis and proliferation in breast tissue of healthy women: influence of age and steroid status. An exploratory study.
European journal of obstetrics, gynecology, and reproductive biology 2006;129(1):96-8.
2006: Hemelaar Majoie; Rosing Jan; Kenemans Peter; Thomassen M Christella L G D; Braat Didi D M; van der Mooren Marius J
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(7):1660-6.
2006: Hemelaar M; Kenemans P; Schalkwijk C G; Braat D D M; van der Mooren M J
No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women.
Human reproduction (Oxford, England) 2006;21(6):1635-42.
2006: Hemelaar Majoie; Kenemans Peter; de Bie Lut; van de Weijer Peter H M; van der Mooren Marius J
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
Fertility and sterility 2006;85(4):979-88.
2006: Verhoeven M O; Hemelaar M; van der Mooren M J; Kenemans P; Teerlink T
Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study.
Journal of internal medicine 2006;259(2):199-208.
2006: Vogelvang Tatjana Elène; van der Mooren Marius Jan; Mijatovic Velja; Kenemans Peter
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
Drugs 2006;66(2):191-221.
2005: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Emeis Jef J; Heijst Johannes A; van der Mooren Marius J
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.
American journal of obstetrics and gynecology 2005;193(4):1384-94.
2005: Hemelaar Majoie; van der Mooren Marius J; van Baal W Marchien; Schalkwijk Casper G; Kenemans Peter; Stehouwer Coen D A
Effects of transdermal and oral postmenopausal hormone therapy on vascular function: a randomized, placebo-controlled study in healthy postmenopausal women.
Menopause (New York, N.Y.) 2005;12(5):526-35.
2005: Verhoeven Marieke O; van der Mooren Marius J; van de Weijer Peter H M; Verdegem Peter J E; van der Burgt Leontine M J; Kenemans Peter;
Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic perimenopausal women: a 12-week randomized, placebo-controlled, double-blind study.
Menopause (New York, N.Y.) 2005;12(4):412-20.
2005: Korstjens Iolente J M; Smolders Raimond G V; van der Mooren Marius J; Kloosterboer Helenius J; Kenemans Peter; Sipkema Pieter
Endothelium-dependent dilatory effects of 3alpha-OH-tibolone in gracilis muscle arterioles of the female Wistar rat.
Menopause (New York, N.Y.) 2005;12(3):340-7.
2005: Vogelvang T E; Leurs J R; Mijatovic V; Willemse J; van der Mooren M J
HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women.
Journal of thrombosis and haemostasis : JTH 2005;3(5):1090-2.
2005: Vogelvang Tatjana E; Mijatovic Velja; van der Mooren Marius J; Pinsdorf Ursula; von Bergmann Klaus; Netelenbos J Coen; Lütjohann Dieter
Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
Maturitas 2005;50(4):312-20.
2005: Smolders R G V; de Meer K; Kenemans P; Jakobs C; Kulik W; van der Mooren M J
Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux.
The Journal of clinical endocrinology and metabolism 2005;90(4):2218-24.
2005: Post Marinka S; Leurs Judith R; van der Mooren Marius J; van Baal W Marchien; Hendriks Dirk F; Stehouwer Coen D A; Kenemans Peter
Different effects of low-dose transdermal and oral oestrogen therapy on procarboxy-peptidase U, an inhibitor of fibrinolysis, in healthy postmenopausal women: a randomised, placebo-controlled study.
Thrombosis and haemostasis 2005;93(3):620-2.
2004: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Teerlink Tom; van der Mooren Marius J
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.
Fertility and sterility 2004;82(6):1540-9.
2004: Vogelvang Tatjana E; Mijatovic Velja; Kenemans Peter; Schalkwijk Casper G; van der Mooren Marius J
Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
The American journal of cardiology 2004;94(9):1205-8.
2004: de Kraker Alyde T; Kenemans Peter; Smolders Raimond G V; Kroeks Maurice V A M; van der Mooren Marius J
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
Maturitas 2004;49(3):253-63.
2004: Smolders R G V; de Meer K; Kenemans P; Teerlink T; Jakobs C; van der Mooren M J
Hormone replacement influences homocysteine levels in the methionine-loading test: a randomized placebo controlled trial in postmenopausal women.
European journal of obstetrics, gynecology, and reproductive biology 2004;117(1):55-9.
2004: Verhoeven Marieke O; van der Mooren Marius J; Coelingh Bennink Herjan J T; van der Linden René F
Effects of high-dose RU-486 treatment on climacteric complaints in hysterectomized postmenopausal women: a 6-week pilot study.
European journal of obstetrics, gynecology, and reproductive biology 2004;115(1):115-6.
2004: van der Mooren M J; Kenemans P
The Million Women Study: a licence to kill other investigations?
European journal of obstetrics, gynecology, and reproductive biology 2004;113(1):3-5.
2004: Gambacciani Marco; de Aloysio Domenico; Elia David; van der Mooren Marius J; Hadji Peyman; Wüster Christian
Quantitative ultrasound (QUS) of bone in the management of postmenopausal women.
Maturitas 2004;47(2):139-49.
2004: Vogelvang Tatjana E; Leurs Judith R; van der Mooren Marius J; Mijatovic Velja; Hendriks Dirk F; Neele Simone J M; Netelenbos J Coen; Kenemans Peter
Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
Menopause (New York, N.Y.) 2004;11(1):110-5.
2004: Smolders Raimond G V; Sipkema Pieter; Kenemans Peter; Stehouwer Coen D A; Van Der Mooren Marius J
Homocysteine impairs estrogen-induced vasodilation in isolated rat arterioles.
Menopause (New York, N.Y.) 2004;11(1):98-103.
2004: Vogelvang Tatjana E; van der Mooren Marius J; Mijatovic Velja
Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
Treatments in endocrinology 2004;3(2):105-15.
2004: van der Mooren Marius Jan; Kenemans Peter
Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.
Drugs 2004;64(8):821-36.
2003: Post Marinka S; van der Mooren Marius J; van Baal W Marchien; Blankenstein Marinus A; Merkus Hans M W M; Kroeks Maurice V A M; Franke Henk R; Kenemans Peter; Stehouwer Coen D A
Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study.
American journal of obstetrics and gynecology 2003;189(5):1221-7.
2003: Hemelaar Majoie; van der Mooren Marius J; Mijatovic Velja; Bouman Anneke A; Schijf Charles P T; Kroeks Maurice V A M; Franke Henk R; Kenemans Peter
Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study.
Menopause (New York, N.Y.) 2003;10(6):550-8.
2003: van der Mooren M J; Franke H R
The Million Women Study: no new evidence to change current opinions.
Maturitas 2003;46(2):99-100.
2003: Post Marinka S; Verhoeven Marieke O; van der Mooren Marius J; Kenemans Peter; Stehouwer Coen D A; Teerlink Tom
Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women.
The Journal of clinical endocrinology and metabolism 2003;88(9):4221-6.
2003: Vogelvang Tatjana E; van der Mooren Marius J; Kamp Otto; Mijatovic Velja; Visser Cees A; Kenemans Peter
Effects of oral and transdermal low-dose estrogen therapy on echocardiographic parameters of cardiac function.
Fertility and sterility 2003;80(3):546-53.
2003: Smolders R G V; van der Mooren M J; Sipkema P; Kenemans P
Estrogens, homocysteine, vasodilatation and menopause: basic mechanisms, interactions and clinical implications.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2003;17(4):339-54.
2003: Post Marinka S; Christella M; Thomassen L G D; van der Mooren Marius J; van Baal W Marchien; Rosing Jan; Kenemans Peter; Stehouwer Coen D A
Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(6):1116-21.
2003: Smolders R G V; van der Mooren M J; Teerlink T; Merkus J M W M; Kroeks M V A M; Franke H R; Stehouwer C D A; Kenemans P
A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels.
Fertility and sterility 2003;79(2):261-7.
2002: Post Marinka S; Rosing Jan; Van Der Mooren Marius J; Zweegman Sonja; Van Baal W Marchien; Kenemans Peter; Stehouwer Coen D A;
Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women.
British journal of haematology 2002;119(4):1017-23.
2002: Post M S; van der Mooren M J; Stehouwer C D A; van Baal W M; Mijatovic V; Schalkwijk C G; Kenemans P
Effects of transdermal and oral oestrogen replacement therapy on C-reactive protein levels in postmenopausal women: a randomised, placebo-controlled trial.
Thrombosis and haemostasis 2002;88(4):605-10.
2002: Brood-van Zanten Monique M A; Barentsen Ronald; van der Mooren Marius J
Hormone replacement therapy and surveillance considerations.
Maturitas 2002;43 Suppl 1():S57-67.
2002: Smolders Ramon G V; van der Mooren Marius J; Kenemans Peter; van der Linden Peter W J; Stehouwer Coen D A; Sipkema Pieter
17 beta-Estradiol induces a rapid, endothelium-dependent, sex-specific vasodilatation in spontaneous constricted rat arterioles.
American journal of obstetrics and gynecology 2002;187(2):375-81.
2002: Thijs A; van Baal W M; van der Mooren M J; Kenemans P; Dräger A M; Huijgens P C; Stehouwer C D A
Effects of hormone replacement therapy on blood platelets.
European journal of clinical investigation 2002;32(8):613-8.
2002: Vogelvang Tatjana E; Mijatovic Velja; Kamp Otto; Netelenbos J Coen; Neele Simone J M; Pines Amos; Kenemans Peter; van der Mooren Marius J
Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
American journal of obstetrics and gynecology 2002;186(4):729-36.
2002: Post M S; Hendriks D F; Van Der Mooren M J; Van Baal W M; Leurs J R; Emeis J J; Kenemans P; Stehouwer C D A
Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
Journal of internal medicine 2002;251(3):245-51.
2002: Smolders Raimond G V; Vogelvang Tatjana E; Mijatovic Velja; van Baal W Marchien; Neele Simone J M; Netelenbos J Coen; Kenemans Peter; van der Mooren Marius J
A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
Maturitas 2002;41(2):105-14.
2001: Post M S; van der Mooren M J; van Baal W M; Neele S J; Netelenbos J C; Kenemans P
Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.
American journal of obstetrics and gynecology 2001;185(3):557-62.
2001: Mijatovic V; van der Mooren M J
Homocysteine in postmenopausal women and the importance of hormone replacement therapy.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2001;39(8):764-7.
2001: van der Mooren M J
Cardiovascular protection by postmenopausal hormone replacement therapy -- the point of lower oestrogen dosages.
Maturitas 2001;38(3):227-9.
2001: Kessel H; Kamp O; Kenemans P; Mijatovic V; van Baal W M; Visser C A; van der Mooren M J
Effects of 15 months of 17 beta-estradiol and dydrogesterone on systolic cardiac function according to quantitative and Doppler echocardiography in healthy postmenopausal women.
American journal of obstetrics and gynecology 2001;184(5):910-6.
2000: Neele S J; Marchien van Baal W; van der Mooren M J; Kessel H; Netelenbos J C; Kenemans P
Ultrasound assessment of the endometrium in healthy, asymptomatic early post-menopausal women: saline infusion sonohysterography versus transvaginal ultrasound.
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2000;16(3):254-9.
2000: Franke H R; van de Weijer P H; Pennings T M; van der Mooren M J
Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial.
Fertility and sterility 2000;74(3):534-9.
2000: van Baal W M; Emeis J J; van der Mooren M J; Kessel H; Kenemans P; Stehouwer C D
Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study.
Thrombosis and haemostasis 2000;83(1):29-34.
1999: van Baal W M; Kenemans P; Stehouwer C D; Peters-Muller E R; van Vugt J M; van der Mooren M J
Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women.
American journal of obstetrics and gynecology 1999;181(6):1365-73.
1999: Van Baal W M; Emeis J J; Kenemans P; Kessel H; Peters-Muller E R; Schalkwijk C G; van der Mooren M J; Stehouwer C D
Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules.
European journal of clinical investigation 1999;29(11):913-21.
1999: van Baal W M; Smolders R G; van der Mooren M J; Teerlink T; Kenemans P
Hormone replacement therapy and plasma homocysteine levels.
Obstetrics and gynecology 1999;94(4):485-91.
1999: de Valk-de Roo G W; Stehouwer C D; Lambert J; Schalkwijk C G; van der Mooren M J; Kluft C; Netelenbos C
Plasma homocysteine is weakly correlated with plasma endothelin and von Willebrand factor but not with endothelium-dependent vasodilatation in healthy postmenopausal women.
Clinical chemistry 1999;45(8 Pt 1):1200-5.
1999: van de Weijer P H; Scholten P C; van der Mooren M J; Barentsen R; Kenemans P
Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
Climacteric : the journal of the International Menopause Society 1999;2(2):101-9.
1999: van Baal W M; Kenemans P; van der Mooren M J; Kessel H; Emeis J J; Stehouwer C D
Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women.
Thrombosis and haemostasis 1999;81(6):925-8.
1999: Mijatovic V; van der Mooren M J; Stehouwer C D; Netelenbos J C; Kenemans P
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1999;13(2):130-44.
1999: van Baal W M; Kenemans P; Emeis J J; Schalkwijk C G; Mijatovic V; van der Mooren M J; Vischer U M; Stehouwer C D
Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women.
Fertility and sterility 1999;71(4):663-70.
1999: Mijatovic V; van der Mooren M J; Kenemans P; de Valk-de Roo G W; Netelenbos C
Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Menopause (New York, N.Y.) 1999;6(2):134-7.
1998: Mijatovic V; Netelenbos C; van der Mooren M J; de Valk-de Roo G W; Jakobs C; Kenemans P
Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
Fertility and sterility 1998;70(6):1085-9.
1998: van Ittersum F J; van Baal W M; Kenemans P; Mijatovic V; Donker A J; van der Mooren M J; Stehouwer C D
Ambulatory--not office--blood pressures decline during hormone replacement therapy in healthy postmenopausal women.
American journal of hypertension 1998;11(10):1147-52.
1998: van der Mooren M J; Mijatovic V; van Baal W M; Stehouwer C D
Hormone replacement therapy in postmenopausal women with specific risk factors for coronary artery disease.
Maturitas 1998;30(1):27-36.
1998: Mijatovic V; Kenemans P; Netelenbos C; Jakobs C; Popp-Snijders C; Peters-Muller E R; van der Mooren M J
Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels.
Fertility and sterility 1998;69(5):876-82.
1998: Mijatovic V; Kenemans P; Jakobs C; van Baal W M; Peters-Muller E R; van der Mooren M J
A randomized controlled study of the effects of 17beta-estradiol-dydrogesterone on plasma homocysteine in postmenopausal women.
Obstetrics and gynecology 1998;91(3):432-6.
1997: Mijatovic V; Kenemans P; Netelenbos J C; Peters-Muller E R; van Kamp G J; Voetberg G A; van de Weijer P H; van der Mooren M J
Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
The Journal of clinical endocrinology and metabolism 1997;82(11):3543-7.
1997: Pines A; Mijatovic V; van der Mooren M J; Kenemans P
Hormone replacement therapy and cardioprotection: basic concepts and clinical considerations.
European journal of obstetrics, gynecology, and reproductive biology 1997;71(2):193-7.
1997: van der Mooren M J; Demacker P N; Blom H J; de Rijke Y B; Rolland R
The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women.
Fertility and sterility 1997;67(1):67-73.
1995: Wouters M G; Moorrees M T; van der Mooren M J; Blom H J; Boers G H; Schellekens L A; Thomas C M; Eskes T K
Plasma homocysteine and menopausal status.
European journal of clinical investigation 1995;25(11):801-5.
1994: van der Mooren M J; Hanselaar A G; Borm G F; Rolland R
Changes in the withdrawal bleeding pattern and endometrial histology during 17 beta-estradiol-dydrogesterone therapy in postmenopausal women: a 2 year prospective study.
Maturitas 1994;20(2-3):175-80.
1994: van der Mooren M J; Wouters M G; Blom H J; Schellekens L A; Eskes T K; Rolland R
Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women.
European journal of clinical investigation 1994;24(11):733-6.
1994: van der Mooren M J; Leuven J A; Rolland R
Effect of conjugated estrogens with and without medrogestone: a prospective study.
Maturitas 1994;19(1):33-42.
1993: van der Mooren M J; Demacker P N; Thomas C M; Borm G F; Rolland R
A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
European journal of obstetrics, gynecology, and reproductive biology 1993;52(2):117-23.
1993: Schijf C P; van der Mooren M J; Doesburg W H; Thomas C M; Rolland R
Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle.
Acta endocrinologica 1993;129(2):130-3.
1992: van der Mooren M J; Demacker P N; Thomas C M; Rolland R
Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
European journal of obstetrics, gynecology, and reproductive biology 1992;47(2):153-60.

Sign-in to see more